210 related articles for article (PubMed ID: 18199343)
1. The seven-year preliminary results of brachytherapy with Iodine-125 seeds for localized prostate cancer treated at a Brazilian single-center.
Franca CA; Vieira SL; Bernabe AJ; Penna AB
Int Braz J Urol; 2007; 33(6):752-62; discussion 762-3. PubMed ID: 18199343
[TBL] [Abstract][Full Text] [Related]
2. Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate.
Lawton CA; Yan Y; Lee WR; Gillin M; Firat S; Baikadi M; Crook J; Kuettel M; Morton G; Sandler H
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e795-801. PubMed ID: 22330999
[TBL] [Abstract][Full Text] [Related]
3. Twelve-month prostate-specific antigen values and perineural invasion as strong independent prognostic variables of long-term biochemical outcome after prostate seed brachytherapy.
Ding W; Lee J; Chamberlain D; Cunningham J; Yang L; Tay J
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):962-7. PubMed ID: 22494584
[TBL] [Abstract][Full Text] [Related]
4. Results of a cohort of 200 hormone-naïve consecutive patients with prostate cancer treated with iodine 125 permanent interstitial brachytherapy by the same multidisciplinary team.
Bolla M; Verry C; Giraud JY; Long JA; Conil M; Abidi R; Troccaz J; Colonna M; Descotes JL
Cancer Radiother; 2014 Nov; 18(7):643-8. PubMed ID: 25286905
[TBL] [Abstract][Full Text] [Related]
5. Outcomes following iodine-125 monotherapy for localized prostate cancer: the results of leeds 10-year single-center brachytherapy experience.
Henry AM; Al-Qaisieh B; Gould K; Bownes P; Smith J; Carey B; Bottomley D; Ash D
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):50-6. PubMed ID: 20005453
[TBL] [Abstract][Full Text] [Related]
6. Prostate brachytherapy with iodine-125 seeds: analysis of a single institutional cohort.
Leite ETT; da Silva JLF; Capelletti E; Haddad CMK; Marta GN
Int Braz J Urol; 2019; 45(2):288-298. PubMed ID: 30735336
[TBL] [Abstract][Full Text] [Related]
7. Oncological impact of neoadjuvant hormonal therapy on permanent iodine-125 seed brachytherapy in patients with low- and intermediate-risk prostate cancer.
Takamoto A; Tanimoto R; Bekku K; Araki M; Sadahira T; Wada K; Ebara S; Katayama N; Yanai H; Nasu Y
Int J Urol; 2018 May; 25(5):507-512. PubMed ID: 29651796
[TBL] [Abstract][Full Text] [Related]
8. Brachytherapy with transperineal (125)Iodine seeds for localized prostate cancer.
Blank LE; Gonzalez Gonzalez D; de Reijke TM; Dabhoiwala NF; Koedooder K
Radiother Oncol; 2000 Dec; 57(3):307-13. PubMed ID: 11104891
[TBL] [Abstract][Full Text] [Related]
9. Localized prostate cancer with intermediate- or high-risk features treated with combined external beam radiotherapy and iodine-125 seed brachytherapy.
da Silva Franca CA; Vieira SL; Carvalho AC; Bernabé AJ; Penna AB
Brachytherapy; 2010; 9(4):307-12. PubMed ID: 20708980
[TBL] [Abstract][Full Text] [Related]
10. Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: analysis of Radiation Therapy Oncology Group study 0019.
Lee WR; Bae K; Lawton C; Gillin M; Morton G; Firat S; Baikadi M; Kuettel M; Greven K; Sandler H
Cancer; 2007 Apr; 109(8):1506-12. PubMed ID: 17340591
[TBL] [Abstract][Full Text] [Related]
11. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
[TBL] [Abstract][Full Text] [Related]
12. Biochemical relapse-free survival in 400 patients treated with I-125 prostate brachytherapy: the Guildford experience.
Nobes JP; Wells IG; Khaksar SJ; Money-Kyrle JF; Laing RW; Langley SE
Prostate Cancer Prostatic Dis; 2009; 12(1):61-6. PubMed ID: 18427571
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.
Zelefsky MJ; Wallner KE; Ling CC; Raben A; Hollister T; Wolfe T; Grann A; Gaudin P; Fuks Z; Leibel SA
J Clin Oncol; 1999 Feb; 17(2):517-22. PubMed ID: 10080594
[TBL] [Abstract][Full Text] [Related]
14. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Efficacy and Toxicity of Low-Dose-Rate ¹²⁵I Prostate Brachytherapy as Monotherapy in Low-, Intermediate-, and High-Risk Prostate Cancer.
Kittel JA; Reddy CA; Smith KL; Stephans KL; Tendulkar RD; Ulchaker J; Angermeier K; Campbell S; Stephenson A; Klein EA; Wilkinson DA; Ciezki JP
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):884-93. PubMed ID: 25962627
[TBL] [Abstract][Full Text] [Related]
16. Permanent prostate brachytherapy with or without supplemental external beam radiotherapy as practiced in Japan: outcomes of 1300 patients.
Yorozu A; Kuroiwa N; Takahashi A; Toya K; Saito S; Nishiyama T; Yagi Y; Tanaka T; Shiraishi Y; Ohashi T
Brachytherapy; 2015; 14(2):111-7. PubMed ID: 25127123
[TBL] [Abstract][Full Text] [Related]
17. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
Hiratsuka J; Jo Y; Yoshida K; Nagase N; Fujisawa M; Imajo Y
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):684-90. PubMed ID: 15183471
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen relapse-free survival in patients with localized prostate cancer treated by brachytherapy.
Joseph J; Al-Qaisieh B; Ash D; Bottomley D; Carey B
BJU Int; 2004 Dec; 94(9):1235-8. PubMed ID: 15610096
[TBL] [Abstract][Full Text] [Related]
19. 125I brachytherapy for localized prostate cancer: a single institution experience.
Guarneri A; Botticella A; Filippi AR; Munoz F; Beltramo G; Casetta G; Giglioli FR; Tizzani A; Ragona R; Ricardi U
Tumori; 2013; 99(1):83-7. PubMed ID: 23549005
[TBL] [Abstract][Full Text] [Related]
20. Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men agedGómez-Iturriaga Piña A; Crook J; Borg J; Lockwood G; Fleshner N
Urology; 2010 Jun; 75(6):1412-6. PubMed ID: 20035986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
